8-K
false000163062700016306272023-05-232023-05-23

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 23, 2023

TREACE MEDICAL CONCEPTS, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

 

 

Delaware

 

001-40355

 

47-1052611

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification Number)

100 Palmetto Park Place

Ponte Vedra, Florida 32081

(Address of principal executive offices, including Zip Code)

Registrant’s telephone number, including area code: (904) 373-5940

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value per share

TMCI

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

 


 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


 

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2023 Annual Meeting of Stockholders of Treace Medical Concepts, Inc. (the “Company”) held on May 23, 2023, the stockholders of the Company voted on the following proposals, each of which is described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 4, 2023:

Proposal 1: Election of Directors.

The stockholders elected, by the votes indicated below, the following nominees to the Company’s Board of Directors to serve as Class I directors for a three-year term of office expiring at the 2025 annual meeting of the stockholders or until their respective successors have been duly elected and qualified:

Name

 

For

 

Withheld

 

Broker Non-Vote

Lance A. Berry

 

49,782,323

 

2,624,816

 

4,279,391

Elizabeth "Betsy" S. Hanna

 

39,914,384

 

12,492,755

 

4,279,391

Jane E. Kiernan

 

49,782,436

 

2,624,703

 

4,279,391

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm.

The stockholders ratified, by the votes indicated below, the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.

For

 

Against

 

Abstain

 

Broker Non-Vote

56,651,839

 

5,348

 

29,343

 

0

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

 

 

 

TREACE MEDICAL CONCEPTS, INC.

 

 

 

 

Date: May 27, 2023

 

By:

/s/ Mark L. Hair

 

 

 

Mark L. Hair

 

 

 

Chief Financial Officer